Improved survival in women versus men with merkel cell carcinoma - 15/05/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background |
Studies have observed that women have better outcomes than men in melanoma, but less is known about the influence of sex differences on outcomes for other aggressive cutaneous malignancies.
Objective |
To investigate whether women and men have disparate outcomes in Merkel cell carcinoma (MCC).
Methods |
Patients with nonmetastatic MCC undergoing surgery and lymph node evaluation were identified from the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier analysis and Cox proportional hazards regression models were used for overall survival, and competing-risks analysis and Fine-Gray models were used for cause-specific and other-cause mortality.
Results |
The NCDB cohort (n = 4178) included 1516 (36%) women. Women had a consistent survival advantage compared with men in propensity score–matched analysis (66.0% vs 56.8% at 5 years, P < .001) and multivariable Cox regression (hazard ratio, 0.68; 95% confidence interval, 0.61-0.75; P < .001). Similarly, women had a survival advantage in the SEER validation cohort (n = 1202) with 457 (38.0%) women, which was entirely due to differences in MCC-specific mortality (5-year cumulative incidence: 16.4% vs 26.7%, P = .002), with no difference in other-cause mortality (16.8% vs 17.8%, P = .43) observed in propensity score–matched patients.
Limitations |
Potential selection bias from a retrospective data set.
Conclusion |
In MCC, women have improved survival compared with men, driven by MCC-related mortality.
Le texte complet de cet article est disponible en PDF.Key words : Merkel cell cancer, National Cancer Data Base, NCDB, SEER, sex
Abbreviations used : CI, HR, MCC, NCDB, OS, SEER
Plan
Funding sources: None. |
|
Disclosure: Dr Zumsteg has served on the external advisory board for the Scripps Proton Therapy Center and has been a consultant for EMD Serono. Dr Tam; Mr Luu; Drs Barker, Gharavi, Hamid, Shiao, Nguyen, Lu, and Ho have no conflicts of interest to declare. |
|
IRB approval status: Reviewed and exempted by the Cedars-Sinai IRB. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?